Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona | withdrawn | N/A | 0 | University of ArizonaOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 |
| clinicaltrials |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | withdrawn | N/A | 0 | Royal North Shore HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | withdrawn | — | 0 | RECORDATI GROUPINDUSTRY | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | withdrawn | N/A | 0 | Herning HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04583553 | Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture(VS-UrineID) | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | withdrawn | Phase 1 | 0 | Haider MahdiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04312191 | Using Meditation for Oncology Anxiety | withdrawn | N/A | 0 | Mellar Davis MDOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT05846165 | InveStigAting Bladder fiELd-cycLing imAging(ISABELLA) | withdrawn | N/A | 0 | University of AberdeenOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | withdrawn | Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Sep 27, 2024 | clinicaltrials |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06536244 | Impact of Perioperative Anesthetic Management on Renal Cancer Progression. | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | withdrawn | Phase 2 | 0 | AdventHealthOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03150745 | Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix | withdrawn | N/A | 0 | Assiut UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | withdrawn | Phase 1 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Jul 5, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 6 | Apr 30, 2024 | clinicaltrials |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | withdrawn | Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05390021 | PET/MRI in Endometrial Cancer | withdrawn | N/A | 0 | Massachusetts General HospitalOTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Agenus Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | withdrawn | N/A | 0 | University Health Network, TorontoOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 0 | Mar 8, 2024 | clinicaltrials |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05335707 | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients(HIIT PCa) | withdrawn | N/A | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.(CANUCK-01) | withdrawn | Phase 2 | 0 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03970863 | Focal Therapy for Localized Prostate Cancer | withdrawn | — | 0 | China Medical University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04304079 | A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery | withdrawn | N/A | 0 | Chinese University of Hong KongOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05035732 | A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study) | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 25, 2024source: clinicaltrials